Loading stock data…
LMAT
$112.04+2.29 (+2.09%)
Market ClosedLast close May 1
LeMaitre Vascular, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LeMaitre Vascular, Inc. in the Healthcare sector is trading at $112.04. The stock is currently near its 52-week high of $118.01, remaining 20.9% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why LMAT maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$112.04
Potential Downside
54.4%
Whystock Fair Value$51.14
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$111.22-0.7%
Range$94.00 – $124.00
Fundamentals
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreser...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.57B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
44.68
Beta
Defensive asset. Lower volatility than the S&P 500.
0.67
Div Yield
Strong income play. Yield provides a meaningful total return floor.
89.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
11.97%
Volume
Today's trading volume
192,743
Recent News
How Investors May Respond To LeMaitre Vascular (LMAT) Profit Boost From Strong Operating Leverage
In the first quarter of 2026, Conestoga Capital Advisors highlighted LeMaitre Vascular as a leading contributor, citing mid-teens revenue growth and a 47% increase in operating income driven by pricing and disciplined expense management. This commentary underscores how effectively LeMaitre Vascular is turning procedure-driven demand into profit growth through operating leverage and tight cost control. Next, we will examine how this stronger operating leverage and profit conversion may...
Lemaitre Vascular (LMAT) is Strengthening Profitability in Vascular Disease Treatment
Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing interest rate expectations. This unrest drove […]
3 Hyped Up Stocks Walking a Fine Line
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
3 Cash-Heavy Stocks Walking a Fine Line
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Is It Too Late To Consider Buying LeMaitre Vascular (LMAT) After Its Strong Share Price Run?
If you are trying to figure out whether LeMaitre Vascular is attractively priced or running ahead of itself, the current share price invites a closer look at what investors are paying for the company. The stock last closed at US$114.36, with returns of 7.6% over 30 days, 42.6% year to date, 33.8% over 1 year and 114.7% over 3 years. This naturally raises questions about how much future potential or risk is already reflected in the price. These moves sit against a broader backdrop of ongoing...